Cite
Chung AW, Anand K, Anselme AC, et al. A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med. 2021;13(624):eabj5070doi: 10.1126/scitranslmed.abj5070.
Chung, A. W., Anand, K., Anselme, A. C., Chan, A. A., Gupta, N., Venta, L. A., Schwartz, M. R., Qian, W., Xu, Y., Zhang, L., Kuhn, J., Patel, T., Rodriguez, A. A., Belcheva, A., Darcourt, J., Ensor, J., Bernicker, E., Pan, P. Y., Chen, S. H., Lee, D. J., Niravath, P. A., & Chang, J. C. (2021). A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Science translational medicine, 13(624), eabj5070. https://doi.org/10.1126/scitranslmed.abj5070
Chung, Andrew W, et al. "A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer." Science translational medicine vol. 13,624 (2021): eabj5070. doi: https://doi.org/10.1126/scitranslmed.abj5070
Chung AW, Anand K, Anselme AC, Chan AA, Gupta N, Venta LA, Schwartz MR, Qian W, Xu Y, Zhang L, Kuhn J, Patel T, Rodriguez AA, Belcheva A, Darcourt J, Ensor J, Bernicker E, Pan PY, Chen SH, Lee DJ, Niravath PA, Chang JC. A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med. 2021 Dec 15;13(624):eabj5070. doi: 10.1126/scitranslmed.abj5070. Epub 2021 Dec 15. PMID: 34910551.
Copy
Download .nbib